Company & Sponsor Intelligence

University of Vermont

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials4

Recruiting1

Completed2

Countries1

Therapeutic footprint

adhdneuromuscularother_neurologyparkinsons

Indexed studies

NCT00619671A Pilot Trial of Rituxan in Refractory Myasthenia Gravis
neuromuscular · United StatesPHASE1, PHASE2

NCT06340841LEMURS SSI: Evaluation of Behavioral Incentives
other_neurology · United StatesPHASE1

NCT02529397Obesity Treatment Enhanced With Working Memory Training
adhd · United StatesNA

NCT01216904Nicotine Treatment of Impulsivity in Parkinson's Disease
parkinsons · United StatesPHASE4

Intelligence layer updated: 2026-10-29 06:17:44.639239+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →